Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 301-310 of 639 results
Cell Death & Disease, 2020 • July 10, 2020
This study investigated the therapeutic effects of RAPA and decompression, in combination or separately, on the histopathology of the injured spinal cord in a rabbit model of SCI. The combination ther...
KEY FINDING: Combination therapy (rapamycin and surgical decompression) significantly reduced intramedullary pressure (IMP) and inhibited apoptosis after SCI.
Spinal Cord Series and Cases, 2020 • July 21, 2020
This pilot study investigated the effectiveness of combining botulinum toxin A (BoNT-A) injections with electrical stimulation (ES) to improve hand function in individuals with incomplete C5–C6 and C6...
KEY FINDING: Treatments produced a significant reduction in motor spasticity (MAS) and better dexterity (NHPT) in the C6–C7 BML with respect to the WML cases
PAIN Reports, 2020 • July 20, 2020
This pilot study investigated the feasibility and safety of conditioning open-label placebo (COLP) as a pharmacobehavioral intervention to decrease opioid consumption in patients with pain in comprehe...
KEY FINDING: Conditioning open-label placebo significantly reduced total opioid consumption by the end of the intervention period.
Cell Death & Disease, 2020 • July 23, 2020
This article is a correction to a previously published paper in Cell Death & Disease. The original publication had an error where Figure 6 was displayed incorrectly. The correction replaces the incorr...
KEY FINDING: The original article had an error in Figure 6.
Eur J Appl Physiol, 2021 • February 1, 2021
This study investigated the effect of Buspirone, a serotonin agonist, on cardiorespiratory adaptations to FES-exercise training in individuals with acute, high-level SCI. The results suggest that Busp...
KEY FINDING: Patients on Buspirone demonstrated greater increases in peak oxygen consumption compared to the control group (+0.24 ± 0.23 vs. +0.10 ± 0.13 L/min, p=0.08).
JBMR Plus, 2020 • August 1, 2020
This study evaluated the effectiveness of denosumab in preserving bone mineral density (BMD) in individuals with subacute spinal cord injury (SCI). The findings indicate that denosumab maintained BMD ...
KEY FINDING: Denosumab maintained aBMD at the distal femur and proximal tibia in persons with a subacute motor-complete SCI.
Qatar Medical Journal, 2020 • June 11, 2020
This case report describes a 29-year-old male with a spinal cord injury who developed myositis while on gabapentin for neuropathic pain. The patient presented with new-onset generalized muscle pain an...
KEY FINDING: Gabapentin use was associated with the development of myositis in a patient with spinal cord injury, characterized by generalized muscle pain and tenderness.
J Cell Mol Med, 2021 • January 1, 2021
This study investigates the neuroprotective effects of Rehmannioside A (Rea) on spinal cord injury (SCI). The findings demonstrate that Rea inhibits the release of inflammatory factors, promotes M2 mi...
KEY FINDING: Rea treatment inhibited the release of pro-inflammatory mediators from microglial cells in vitro and promoted M2 polarization, protecting co-cultured neurons from apoptosis by suppressing NF-κB and MAPK signaling pathways.
Exp Neurol, 2021 • April 1, 2021
This study investigates the effects of pharmacologically increasing KCC2 activity using CLP257 on spasticity symptoms after chronic SCI in rats. The study also explores how this pharmacological approa...
KEY FINDING: Increasing KCC2 activity with CLP257 improved the rate-dependent depression of the H-reflex in sedentary animals after chronic SCI, indicating improved reflex modulation.
Spinal Cord Series and Cases, 2021 • January 1, 2021
This retrospective study analyzed data from the Rochester Epidemiology Project to determine the prevalence of cholesterol-lowering agent use after SCI and its impact on motor function recovery. The st...
KEY FINDING: 30% of individuals with SCI had a prescription for a cholesterol-lowering agent.